COMPASS Pathways (NASDAQ:CMPS) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a research note released on Tuesday morning,Benzinga reports. The firm currently has a $45.00 target price on the stock.

Other analysts also recently issued research reports about the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th. Stifel Nicolaus assumed coverage on shares of COMPASS Pathways in a report on Thursday, February 27th. They issued a “buy” rating and a $11.00 price objective for the company. Finally, Canaccord Genuity Group dropped their price target on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, February 28th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $21.83.

COMPASS Pathways Stock Up 4.9 %

CMPS opened at $3.85 on Tuesday. The company has a market cap of $263.42 million, a PE ratio of -1.75 and a beta of 2.28. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. COMPASS Pathways has a twelve month low of $3.17 and a twelve month high of $11.90. The company has a 50-day moving average price of $4.05 and a 200 day moving average price of $5.19.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). Sell-side analysts expect that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Trading of COMPASS Pathways

Hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of COMPASS Pathways during the 4th quarter worth approximately $41,000. Flagship Harbor Advisors LLC purchased a new position in shares of COMPASS Pathways during the 4th quarter worth approximately $43,000. Wealthfront Advisers LLC purchased a new position in shares of COMPASS Pathways during the 4th quarter worth approximately $43,000. Conservest Capital Advisors Inc. boosted its position in shares of COMPASS Pathways by 28.9% during the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock worth $51,000 after purchasing an additional 3,000 shares during the period. Finally, Simplify Asset Management Inc. purchased a new position in shares of COMPASS Pathways during the 4th quarter worth approximately $54,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.